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A B S T R A C T
2-Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key regulator of
neurotransmitter release. 2-AG is an endocannabinoid that activates the cannabinoid CB1 receptor. It is involved
in a wide array of (patho)physiological functions, such as emotion, cognition, energy balance, pain sensation and
neuroinﬂammation. In this review, we describe the biosynthetic and metabolic pathways of 2-AG and how
chemical and genetic perturbation of these pathways has led to insight in the biological role of this signaling
lipid. Finally, we discuss the potential therapeutic beneﬁts of modulating 2-AG levels in the brain.
1. Introduction
2-Arachidonoylglycerol (2-AG) is one of the most extensively stu-
died monoacylglycerols. It acts as an important signal and as an in-
termediate in lipid metabolism [1,2]. It was ﬁrst isolated from canine
gut and identiﬁed as an endogenous ligand for the cannabinoid re-
ceptors in 1995[3,4]. 2-AG behaves as a full agonist for the cannabinoid
CB1 and CB2 receptors [5–8], which are also modulated by Δ9-tetra-
hydrocannabinol (Δ9-THC), the main psychoactive constituent of the
plant Cannabis sativa [9]. The CB1 receptor is expressed throughout the
body, but it is most extensively studied in the central nervous system
(CNS), where it is the most highly expressed G protein-coupled receptor
(GPCR) [10,11]. While CB2 receptor appears to be expressed in the CNS
only upon diﬀerent insults [12], its predominant localization on im-
mune cells is in line with its role in modulating immune responses
[13–15]. Several other endogenous biomolecules also interact with CB1
and CB2 receptors, including N-arachidonoylethanolamine (ananda-
mide; AEA) [16], virodhamine, N-arachidonoyldopamine (NADA) and
noladin ether (see Pertwee et al. [17] for their in vitro binding aﬃ-
nities). 2-AG and AEA are considered to be the most important en-
docannabinoids. Of note, brain 2-AG levels are ~170 times higher than
those of AEA [18]. It is now well established that 2-AG is synthesized
“on demand” and acts as a retrograde messenger that inhibits neuro-
transmitter release at both inhibitory and excitatory synapses, thereby
mediating various forms of long- and short-term plasticity [19–22].
Activation of the CB1 and CB2 receptors by 2-AG is associated with
many physiological processes, including inﬂammation [23], food intake
[24–26], locomotor activity [27,28], learning and memory [29,30],
epileptogenesis [31], neuroprotection [32], pain sensation [33], mood
[34,35], stress and anxiety [36], addiction [37], and reward [38]. CB1
receptor signaling is tightly regulated by biosynthetic and catabolic
enzymes that control 2-AG levels (Fig. 1). 2-AG and AEA and the CB
receptors, together with the biosynthetic and catabolic enzymes of 2-
AG, constitute an endogenous signaling system termed “the en-
docannabinoid system”. The aim of this review is to describe the phy-
siological role of 2-AG within the brain with a focus on food intake and
metabolism, neuroinﬂammation, anxiety, addiction and pain. Further-
more, it is discussed how perturbing 2-AG biosynthesis and degradation
may facilitate insights into these physiological functions.
2. 2-AG biosynthesis
The biosynthesis of 2-AG can be divided in two main pathways: a
signaling pathway that starts from phosphatidylinositol-4,5-bispho-
sphate (PIP2), and a metabolic pathway that uses sn2-arachidonate-
containing triglycerides (Fig. 1). PIP2 is converted into two important
second messengers by phospholipase Cβ (PLCβ) or phospholipase γ
(PLCγ): diacylglycerol (DAG) and inositol-1,4,5-triphosphate
[18,41,42]. PLCβ uses Ca2+ as a cofactor, and acts as a coincidence
detector by integrating i) the signals coming from Gq-coupled receptor
activation, and ii) the inﬂux of extracellular Ca2+ via ionotropic re-
ceptors and voltage-gated calcium channels [18,43–47]. The metabolic
pathway involves the hydrolysis of triglycerides by hormone-sensitive
lipase, carboxyl esterase and other lipases to sn2-arachidonoylglycerol
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containing diglycerides [18]. At this point the two pathways converge
and the diglycerides are further processed by two isoforms of a sn1-
speciﬁc diacylglycerol lipase, diacylglycerol lipase-α and -β (DAGL-α
and -β) [48]. The DAG lipases hydrolyze diacylglycerols at the sn1
position, generating 2-AG and a fatty acid. In addition, DDHD domain-
containing protein 2 (DDHD2) has recently been reported to possess
also the ability to hydrolyze DAG [49]. Partially puriﬁed DDHD2 from
rat brain, and rat DDHD2 expressed in Chinese hamster ovary (CHO)
cells exhibited DAGL activity in vitro. However, Inloes et al. generated a
DDHD2 KO mouse, which revealed that DDHD2 is a principal trigly-
ceride lipase in vivo [50]. Thus, further research is required to establish
the physiological relevance of this pathway for eﬀective 2-AG bio-
synthesis in the brain.
2-AG can also be generated via an alternative pathway by PIP2
phosphatase, followed by hydrolysis of the sn1-ester by phospholipase
A1 to generate 2-arachidonoyl-LPI. In a ﬁnal step, the phosphate is re-
moved by lysophospholipase C (lysoPLC) to form 2-AG [51] In 2002,
lysophospatidic acid was found indeed in rat brain. This lipid could be
quickly converted to 2-AG by 2-LPA phosphatase [52]. Of note, 2-AG
can also be processed to 2-arachidonoyl LPA by monoacylglycerol ki-
nase and converted back to 2-AG by LPA-phosphatase. Although these
alternative pathways may provide 2-AG, DAGLs are still considered the
most important enzymes for its biosynthesis, on the basis of both se-
lective DAGL inhibitor studies and DAGL-α/-β KO studies [53–55].
2.1. Diacylglycerol lipase α and β
The enzymatic activity that hydrolyses the sn-1-acyl chain from 1,2-
diglycerides yielding 2-AG in human platelets was ﬁrst detected by
Prescott and Majerus in 1983 [72]. Since then, considerable eﬀorts
were undertaken to characterize and isolate the enzyme from bovine
brain [73,74], and it was not until 2003 that two enzymes were iden-
tiﬁed, cloned and designated as DAGL-α and -β [48]. The human genes
show a high homology compared to those of mouse, 97% for DAGL-α
and 79% for DAGL-β. These enzymes structurally diﬀer by the absence
of a large C-terminal tail in DAGL-β compared to DAGL-α. Transfection
of the DAGL-α and DAGL-β genes in COS cells resulted in enzymes with
a molecular weight of ~120 kD for DAGL-α and ~70 kD for DAGL-β.
Molecular characterization of these two enzymes revealed that they are
plasma membrane-bound serine hydrolases speciﬁc for hydrolysis of an
acyl chain at the sn1-position of diacylglycerols [48].
The C-terminal tail of DAGL-α plays an important regulatory func-
tion. Its phosphorylation by calcium/calmodulin-dependent protein
kinase II (CaMKII) at Ser782 and Ser808 signiﬁcantly reduces enzyme
activity [75]. The C-terminal tail of DAGL-α contains also a consensus
motif (PPxxF) for binding with the coiled coil domain of homer pro-
teins. Homers are adaptor proteins that interact with many diﬀerent
proteins, including the metabotropic glutamate receptor. An interaction
between homer-1b and homer-2 with DAGL-α was shown to be im-
portant for DAGL-α localization at the plasma membrane, but is not
Fig. 1. Overview of the major biosynthetic and metabolic pathways for 2-AG. PLCβ: phospholipase Cβ, PLCγ: phospholipase Cγ, HSL: hormone sensitive lipase, PIP2:
phosphatidylinositol-4,5-bisphosphate, PI: Phosphatidylinositol, TAG: triacylglycerol, DAG: diacylglycerol, PLA1: phospholipase A1, 2-AG-LPI: 2-arachidonoyl lyso-
phosphatidylinositol, Lyso-PLC: lyso-phospholipase C, MAG kinase: monoacylglycerol kinase, 2-LPA phosphatase: 2-lysophospatidic acid phosphatase, 2-AG: 2-
arachidonoyl glycerol, 2-AG-LPA: 2-arachidonoylglycerol lysophosphatidic acid, CYP2J2: cytochrome P2J2, LOX-12: lipoxygenase 12, LOX-15-2: lipoxygenase 15-2,
MAGL: monoacylglycerol lipase, ABHD2, 6, 12: alpha/beta hydrolase domain containing 2, 6, 12, COX1/2: cyclooxygenase 1/2, LYPLA2: lysophospholipase 2, 11,
12-EET-G: 11, 12-epoxyeicosatrienoic acid glycerol ester, 14, 15-EET-G: 14, 15-epoxyeicosatrienoic acid glycerol ester, PGE2-G: prostaglandin E2 glycerol ester, PGE2:
prostaglandin E2, 12-HETE-G: 12-hydroxyeicosatetraenoic glyceryl ester, 15-HETE-G: 15-hydroxyeicosatetraenoic glyceryl ester. PGES: Prostaglandin E synthase. R
= predominantly stearoyl, but it can also represent lipids of diﬀerent chain length and/or degree of saturation [39,40].
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required for its catalytic activity [76]. Moreover, the surface expression
of DAGL-α is dynamic, undergoing endocytosis and recycling back to
the postsynaptic membrane [77]. DAGL-α cycling between the cell
surface and intracellular endosomal compartments is regulated by
protein kinase C (PKC). Rapid degradation and replenishment of DAGL-
α upon inhibition with covalent inhibitor DH376 indicated a short
protein half-life [39]. Taken together, these observations indicate that
activity, expression and localization of DAGL-α enables a tight spatio-
temporal control on 2-AG synthesis and release.
Two landmark studies have shown the contribution of DAGL-α and
DAGL-β to the in vivo biosynthesis of 2-AG. Congenital deletion of
DAGL-α or -β reduced 2-AG levels in the brain by 80% and 50%, re-
spectively [53,54]. In the liver of DAGL-α KO mice a 50% reduction in
2-AG was observed, whereas in DAGL-β KO mice it was almost com-
pletely abolished (> 90% reduction), revealing a tissue speciﬁc con-
tribution of each enzyme. DAGL-α is highly expressed in neurons and is
found at (peri)post-synaptic sites, while DAGL-β is relatively more ac-
tive in microglia [78–82]. 2-AG acts as a retrograde neurotransmitter.
Stimulation of 2-AG release by depolarization of postsynaptic neurons,
activation of Gq/11-coupled receptors and a combination of Gq/11-cou-
pled receptor activation and Ca2+ elevation suppresses synaptic
transmission at both excitatory and inhibitory synapses, that is in de-
polarization-induced suppression of inhibition(DSI) or excitation DSE),
respectively. This eﬀect was absent in DAGL-α KO brain slices, but
DAGL-β knockout brain slices maintained retrograde inhibition of sy-
naptic transmission [53,54].
Recently multiple, highly selective pharmacological tools have been
developed to modulate DAGL activity, but subtype selective inhibitors
for each DAGL isoform have not been reported yet. See Kohnz et al.
[83] and Janssen et al. [84] for recent reviews on DAGL inhibitors. Dual
DAGL-α/β inhibitors used in parallel with DAGL-α and DAGL-β
knockout mice have contributed to our understanding of the physio-
logical role of 2-AG in health and disease models, such as synaptic
transmission, neuroinﬂammation [39], anxiety [85] and food intake
[86]. For example, Baggelaar et al. reported the highly selective dual
DAGL-α/β inhibitor LEI105[58] and Ogasawara et al. disclosed the ﬁrst
CNS active DAGL inhibitors DO34 and DH376 (Table 1) [39]. These
inhibitors were instrumental to unequivocally establish that 2-AG
production is ‘on demand’ during various forms of short-term synaptic
plasticity in hippocampal and cerebellar slices [39,58,87]. Lipid ana-
lysis revealed an extensive rewiring of lipid metabolic pathways in the
brain upon inactivation of DAGLs by DO34 and DH376. Not only levels
of sn1-stearyl-2-arachidonoyl-glycerol, but also levels of sn1-palmitoyl-
2-arachidonoyl-glycerol, sn1-palmitoyl-2-stearyl-glycerol, sn1-oleyl-2-
stearyl-glycerol were elevated in DAGL-α KO and in inhibitor-treated
mouse brains. Concomitantly, 2-AG and other monoacylglycerols, i.e.
palmitoyl-glycerol, oleoyl glycerol and docosahexaenoyl-glycerol, were
reduced. Interestingly, these other monoacylglycerols are important
signaling lipids in their own right, which should be taken into account
when analyzing the physiological eﬀect of disrupting DAGL function.
3. 2-AG degradation
2-AG is metabolized by multiple enzymes (Fig. 1), all of which lead
to a decrease in 2-AG levels and signaling. The predominant pathway
for 2-AG metabolism is the hydrolysis of the ester bond into arachidonic
acid (AA) and glycerol. Blankman et al. showed that MAGL is re-
sponsible for ~85% of 2-AG hydrolysis in mouse brain, whereas α,β-
hydrolase domain-containing protein 12 (ABHD12) and ABHD6 ac-
count for ~9% and ~4%, respectively [88]. Also cyclooxygenase
(COX), lipoxygenase (LOX), and cytochrome P450 (CytP450) enzymes
have been reported to use 2-AG as a substrate. Recently, ABHD2 has
been reported to hydrolyze 2-AG in spermatozoa. This enzyme has a
relatively high expression in the brain compared to other tissues. These
metabolic enzymes are described in more detail below.
3.1. Monoacylglycerol lipase (MAGL)
In the early sixties, it was demonstrated that two distinct proteins
from lipoprotein lipase were involved in the hydrolysis of triacylgly-
cerol in adipose tissue of both rats and rabbits. Hormone sensitive lipase
(HSL) was shown to convert triacylglycerol to monoacylglycerols, and
subsequently a dedicated lipase hydrolyzed monoacylglycerols to free
fatty acids and glycerol [89]. Partial puriﬁcation of the mono-
acylglycerol lipase activity convincingly showed its preference for
monoacylglycerols over diacylglycerols and triacylglycerols [90]. It
took until 1997 before a speciﬁc monoacylglycerol lipase (MAGL) was
cloned [91]. MAGL consists of two tissue speciﬁc isoforms with a mo-
lecular weights of 33 kD and 36 kD, which could reﬂect diﬀerent splice
variants [91–94]. It is an ubiquitously expressed serine hydrolase
containing the typical GXSXG motif with Ser-122, Asp-239 and His-269
forming the catalytic triad [61,64]. The enzyme associates with mem-
branes and its active site resides in the cytosol. MAGL has a broad
substrate speciﬁcity and hydrolyses monoacylglycerols with diﬀerent
chain lengths and degrees of unsaturation, including 2-palmitoylgly-
cerol, 2-stearoylglycerol and 2-oleoylglycerol [95–97]. Hydrogen per-
oxide-mediated MAGL sulfenylation at C-201 and C-208 reduces en-
zyme activity [98].
The interest in MAGL was boosted when the enzyme was linked to
the endocannabinoid system. The subsequent development of MAGL KO
mice [59,60,83,94,99] and selective, in vivo active MAGL inhibitors,
such as JZL184 and MJN110 (Table 1), have signiﬁcantly advanced our
understanding of the role of MAGL in vivo [59,100–103]. The tissue
speciﬁc role of MAGL was investigated using the MAGL inhibitor
JZL184. The levels of 2-AG were increased 8-fold in the brain, whereas
in peripheral tissues such as liver, kidney, spleen, brown adipose tissue
(BAT) and heart their increase was less evident. No signiﬁcant changes
were observed in the testis, lung and white adipose tissue (WAT) [94].
Interestingly, C16:0 and C18:1 MAGs were increased in peripheral tis-
sues to a larger extent than in the brain, suggesting a more general
metabolic function of MAGL in peripheral tissues [94,102]. MAGL has a
relatively high expression in neurons compared to astrocytes and mi-
croglia. In contrast to the major 2-AG biosynthetic enzyme DAGL-α,
MAGL is positioned presynaptically along with CB1 receptor. Evidence
for the role of MAGL in retrograde 2-AG signaling was shown in elec-
trophysiology experiments in cultured neurons and brain slices, where
both MAGL inhibitors and genetic deletion of MAGL enhanced DSI/DSE
[104–111].
Chronic disruption of MAGL activity severely decreased the ability
of mouse brain to hydrolyze 2-AG, leading to a>10 fold increase of 2-
AG in the brain. Interestingly, a milder but still signiﬁcant increase of 2-
AG levels was observed in thymus, spleen and liver of MAGL KO mice
[102]. Noteworthy, levels of other monoacylglycerols were also in-
creased in vivo. Tonic elevation of 2-AG levels by MAGL knockout in the
brain causes adaptations in CB1 receptor activity. MAGL knockout mice
exhibited impaired endocannabinoid-dependent synaptic plasticity,
physical dependence and desensitization of brain CB1 receptors [101].
Repeated administration of the selective MAGL inhibitor JZL184 mir-
rored the observations in the knockout mice and caused CB1 receptor
desensitization, tolerance to CB1 receptor agonists and down regulation
of CB1 receptors [101]. This evidence points to a major role for MAGL
in regulating bulk 2-AG levels, and raises the question of whether a
therapeutic window to elevate 2-AG levels can be achieved without
desensitizing CB1 signaling. Several studies have addressed this ques-
tion and investigated the eﬀect of partial blockade of MAGL using low
doses of JZL184 [112–115]. Chronic JZL184 dosing for ~7 days up to 8
mg/kg per day did not lead to CB1 receptor desensitization or beha-
vioral tolerance, while chronically treated animals with 16 mg/kg
JZL184 per day did show tolerance [114,115]. Thus, it appears possible
to elevate 2-AG levels without desensitizing CB1 receptor.
Noteworthy, the content of AA, the product of 2-AG hydrolysis,
dropped signiﬁcantly in the brain devoid of MAGL and DAGL activity
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Table 1
Inhibitors and ligands discussed throughout this review.
Enzyme Struucture Name Chemotype Oﬀ target(s)
DAGL O-7460 Fluoro phosphonates KIAA1363[56]
O-5596 Fluoro phosphonates None reported [57]
KT172 1,2,3-Triazole ureas ABHD6[55]
DH376 1,2,3-Triazole ureas ABHD6[39]
CES1C
LIPE
BCHE
DO034 1,2,3-Triazole ureas DAGL [39]
CES1C
PLA2G7
ABHD2
PAFAH2
LEI105 a-Keto heterocycles None reported [58]
MAGL JZL184 carbamates FAAH [59]
MJN110 carbamates ABHD6 (minor) [60]
(continued on next page)
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Table 1 (continued)
Enzyme Struucture Name Chemotype Oﬀ target(s)
MAGL Compound 4aa 1,2,4-triazole urea LYPLA1[61]
LYPLA2
Compound 21b Biphenyl-ester FAAH (minor) [62]
URB602 carbamate FAAH [63]
OMDM169 β-lactone FAAH [64]
DAGL-α
SAR127303 carbamate ABHD6[29]
ABHD6 KT195 1,2,3-Triazole urea PLA2G15[55]
WWL70 carbamate None reported [65]
COX-2 LM-4131 Indomethacin Morpholinylamide None reported [66]
CB1 Rimonabant pyrazole-3-carboxamide ABHD12[67]
TRPV3
TRPA1 (minor)
TRPM8 (minor)
MC3
MT1
(continued on next page)
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[39,101,102]. This indicates that the DAGL-MAGL axis is responsible to
a large extent for the free AA pool in the brain. Consequently, the ac-
tivity of MAGL and DAGL aﬀected levels of pro-inﬂammatory pros-
taglandins PGE2 and PGD2, which are oxidative metabolites of AA, and
points to DAGL-MAGL axis as a key pathway for the regulation of
neuro-inﬂammatory responses [39,116].
3.2. α,β-Hydrolase domain-containing 6 protein (ABHD6)
ABHD6 is part of a superfamily of proteins having an α,β-hydrolase
fold [117]. It is a membrane-bound protein consisting of 337 amino
acids and has a mass of 38 kD [88]. It is a serine hydrolase that contains
a catalytic triad with the typical GXSXG motif surrounding the catalytic
Ser-148; the other two members of the catalytic triad are Asp-278 and
His-306 [118]. mRNA expression analysis in mice showed that ABHD6
is ubiquitous in the body with relatively high expression in BAT and the
brain [119]. In the human cortex mRNA expression of ABHD6 steadily
increased from neonatal age until adulthood [120]. It is postulated that
ABHD6 is membrane bound, with its active site facing the cytosol.
ABHD6 was responsible for ~4% of the total 2-AG hydrolysis in mouse
brain homogenates [88]. Several selective inhibitors (e.g. KT195 and
WWL70 (Table 1)) have been developed to study ABHD6 function
[65,121–123]. Endogenous ABHD6 was responsible for ~50% of 2-AG
degradation in microglial BV-2 cells. In Neuro2A cells, 2-AG levels were
increased after inhibition with the selective ABHD6 inhibitor KT195
(Table 1) [55]. Both Neuro2A and BV-2 cells lack MAGL activity,
therefore ABHD6 is an important player in 2-AG hydrolysis in these cell
types. Many studies have focused on the role of ABHD6 in 2-AG me-
tabolism and endocannabinoid signaling in the brain. Electron micro-
scopy and immunoﬂuorescence experiments revealed localization of
ABHD6 in postsynaptic dendrites in adult mouse brain, whereas MAGL
is predominantly expressed pre-synaptically [124], thus positioning
ABHD6 at the site of 2-AG production. Inhibition of ABHD6 in pre-
frontal cortical brain slices by the selective inhibitor WWL70 (Table 1)
could reduce CB1 receptor-mediated long-term depression (LTD) [124].
DSI or DSE in autaptic hippocampal neurons were not reduced by in-
hibition of ABHD6 [109,125,126]. It is suggested that ABHD6 is an
interesting drug target for moderate elevation of 2-AG levels. For ex-
ample, inhibition of ABHD6 has anti-inﬂammatory and neuroprotective
eﬀects in a mouse model of traumatic brain injury and multiple
sclerosis, and shows antiepileptic activity [127–129]. Interestingly,
ABHD6 has recently been reported to negatively regulate surface de-
livery and synaptic function of the α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) receptors, which are ionotropic
glutamate receptors mediating synaptic transmission. ABHD6 over-
expression in neurons could drastically reduce excitatory neuro-
transmission mediated by the AMPA receptors independently of its
hydrolytic activity, thereby possibly contributing to its anti-epileptic
activity [130].
3.3. α,β-Hydrolase domain-containing 12 protein (ABHD12)
ABHD12 belongs to the same α,β-hydrolase fold-containing super-
family as ABHD6 [117]. ABHD12 is a membrane-bound protein with an
extracellularly oriented active site [88,131]. It is a 398 amino acid
containing enzyme with a molecular weight of 45 kD. It is a serine
hydrolase having a lipase motif (GTSMG) and a catalytic triad formed
by Ser-246, Asp-333 and His-372 [118]. ABHD12 contributes approxi-
mately ~9% of the total 2-AG metabolism in mouse brain homogenates
[88]. Loss-of-function mutations in the ABHD12 gene cause the human
neurodegenerative disorder PHARC (polyneuropathy, hearing loss,
ataxia, retinosis pigmentosa, and cataract) [132]. ABHD12 transcripts
are highly expressed in the brain, with a signiﬁcant enrichment in
microglia [133]. No selective ABHD12 inhibitors are as yet available,
but the generation of transgenic mice with congenital deletion of
ABHD12 has greatly facilitated our understanding of its biological role
[134]. ABHD12 knockout mice showed PHARC-like symptoms such as
hearing disruptions, muscle weakness and ataxia. Importantly, these
mice showed high elevations in lysophosphatidylserines (LPS), whereas
the 2-AG hydrolyzing capacity of ABHD12 knockout mice was not
signiﬁcantly diﬀerent compared to wild-type counterparts. In line with
this, ABHD12 overexpression did not aﬀect DSE [109]. However, after
incubation with a MAGL inhibitor, a signiﬁcant reduction in residual 2-
AG metabolism was observed in the ABHD12 KO versus wild-type mice.
This suggests that ABHD12 plays a more specialized role and might be
recruited when there is insuﬃcient 2-AG hydrolyzing capacity. How-
ever, there are no data to support the notion that endogenous ABHD12
hydrolyses 2-AG in vivo. Identiﬁcation of selective inhibitors that allow
spatiotemporal control of ABHD12 activity will be a crucial tool to
elucidate the actual role of this enzyme in 2-AG metabolism.
3.4. α,β-Hydrolase domain-containing protein 2 (ABHD2)
ABHD2 is another member of the α,β-hydrolase fold-containing
superfamily. The enzyme is a serine hydrolase with a classical Ser-207,
His-376, Asp-345 catalytic triad. ABHD2 is predicted to be a single pass
type-II membrane protein. The expression of the enzyme is highest in
lung, brain and adrenal glands [119]. Knockdown of ABHD2 using
Table 1 (continued)
Enzyme Struucture Name Chemotype Oﬀ target(s)
Endocannabinoid transport AM404 arachidonoylamide CB1[68]
VR1 vanilloid
receptor [69]
UCM707 arachidonoylamide CB2[70]
CB1 (minor)
OMDM-2 oleylamide CB1 (minor) [71]
a Compound 21: Benzo [d][1,3]dioxol-5-ylmethyl 6-([1,1'-biphenyl]-4-yl)hexanoate, named compound 4a in Brindisi et al. [61].
b Compound 4a: trans-(1-(1-(1H-1,2,4-Triazole-1-carbonyl)piperidin-4-yl)-4-benzo[d][1,3]dioxol-5-yl)-3-(4-ﬂuorophenyl)azetidin-2-one, named compound 21 in
Hernandez-Torres et al. [62].
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antisense oligonucleotides and gene trapping techniques was used to
support an essential role of 2-AG in Hepatitis B virus propagation [135].
ABHD2 appears to play an important role in chronic diseases involved
in monocyte/macrophage recruitment, such as atherosclerosis and
emphysema [136,137]. It was not until recently that ABHD2 was linked
to 2-AG metabolism [138]. The enzyme is highly expressed in sper-
matozoa and acts as a progesterone-dependent hydrolase. Activation of
ABHD2 reduces inhibition of sperm calcium channel CatSper by 2-AG,
which leads to calcium inﬂux and stimulates sperm activation. No in-
hibitors for ABHD2 have been reported to date, and the actual con-
tribution of ABHD2 to 2-AG metabolism in the brain requires further
investigation. The cross-talk between progesterone and ABHD2-de-
pendent endocannabinoid metabolism appears of major interest, and
clearly extends previous data on the ability of progesterone to control
anandamide-hydrolase FAAH expression in human lymphocytes [139],
of estrogen to control FAAH expression in mouse Sertoli cells [140], of
cholesterol to modulate the CB1 cannabinoid receptor at a distinct
CRAC sequence [141], and of pregnenolone to control CB1 speciﬁc
signaling by acting at a speciﬁc amino acid residue [142]. Overall, this
cross-talk brings about a type of regulation whereby 2-AG is con-
tinuously produced to block CatSper, unless progesterone stimulates its
hydrolysis by ABHD2 [138]. Therefore, the widely accepted dogma of
the “on demand” synthesis of 2-AG, that suggests that this compound
acts only upon stimulus-dependent release from phospholipid pre-
cursors, might not hold true in all tissues extending previous observa-
tions on AEA [143].
3.5. Cyclooxygenase-2 (COX-2)
Cyclooxygenases play an important role in inﬂammation and exist
in two isoforms: cyclooxygenase-1 and -2 (COX-1 and COX-2). The
expression of COX-2 is increased in inﬂammatory processes and is es-
sential for the oxidation of AA to prostaglandins [144]. In contrast to
the constitutively expressed COX-1, which has a strong preference for
substrates with a free carboxylate group, COX-2 metabolizes both AA
and 2-AG with similar Kcat and Km [145,146]. Several papers suggest
that COX-2 plays a role in terminating 2-AG signaling in the CNS. For
instance, Kim and Alger showed that inhibition of COX-2 prolonged DSI
in hippocampal slice preparations [147]. A later study in cultured
hippocampal neurons showed that the duration of DSI in a sub-
population of interneurons was inﬂuenced by both MAGL and COX-2
activity [125]. Substrate-selective inhibitors for COX-2 have been de-
veloped, which selectively block the oxidation of 2-AG and AEA but not
of AA [66,148]. The substrate selective inhibitor LM-4131 (Table 1)
could increase 2-AG levels in RAW264.7 cells and intraperitoneal (IP)
injection of this inhibitor led to an in vivo increase of 2-AG levels in the
brain [66].
COX-2-mediated oxidation of 2-AG produces the prostaglandin
glyceryl ester PGE2-G (Fig. 1). Most of the eﬀects of substrate selective
blockade of COX-2 appear to be caused by changes in PGE2-G con-
centrations rather than to be mediated by the minor alterations in 2-AG
levels [66]. PGE2-G is a multifunctional signaling molecule that plays a
role in pain, immunomodulation, and synaptic plasticity [149–151].
The receptor for PGE2-G has not been identiﬁed yet, but the actions of
PGE2-G are mediated through extracellular signal-regulated kinase
(ERK), p38 mitogen-activated protein kinase (MAPK), IP3, and NF-κβ
[151]. In contrast to the anti-nociceptive and anti-inﬂammatory role of
2-AG, the COX-2 metabolite PGE2-G produces hyperalgesia and en-
hances inﬂammation-induced neurodegeneration [149,151,152]. Of
note is that 2-AG suppresses elevation of COX-2 expression via a CB1
receptor-mediated mechanism involving PPARγ and the MAPK/NFκ-B
signaling pathway [153,154]. PGE2-G can be further processed by ly-
sophospholipase A2 (LYPLA2) to generate PGE2 [155].
3.6. Lipoxygenase
Lipoxygenases are a family of non-heme iron containing dioxy-
genases that catalyze the oxidation of polyunsaturated fatty acids with
one or more (1Z,4Z)-pentadiene moieties [156]. This oxidation gen-
erates the corresponding (1S,2E,4Z)-hydroperoxides. Moody et al.
showed that 12-lipoxygenase (12-LOX) oxygenates glycerol esters to-
wards 12-hydroxyeicosatetraenoic (12-HETE) glyceryl ester [157].
Kozak et al. screened a panel of 6 lipoxygenases for their 2-AG oxyge-
nating properties, and found that 15-LOX-1 and 15-LOX-2 also catalyze
the oxygenation of 2-AG towards 15-HETE-glyceryl ester [158]. More-
over, among a series of structurally related arachidonoyl esters, 2-AG
was the optimal substrate for 15-LOX oxygenation. 2-AG treatment of
COS-7 cell transfected with 15-LOX led to the biosynthesis and excre-
tion of 15-HETE-G. Van der Stelt et. al. investigated the aﬃnity of LOX
metabolites of 2-AG for the cannabinoid receptors, and found that 15-
HETE-1-AG has moderate aﬃnity for CB2 but not for CB1 receptor
[159]. However, to date in vivo conversion of 2-AG by 15-LOX or 12-
LOX has not been reported yet, therefore the physiological role of this
pathway remains to be established.
3.7. Cytochrome P450
Cytochrome P450 (CYP450) is a family of heme-containing oxida-
tive enzymes involved in drug metabolism, that can also use en-
dogenous lipids like 2-AG as substrates [160,161]. Two epoxide re-
gioisomers (2-11, 12- and 2-14, 15-epoxyeicosatrienoic acid glycerol
ester (EET-EG)) of CYP450-generated metabolites of 2-AG have been
isolated from rat kidney and spleen, whereas 2-14, 15-EET-EG was also
detected in the brain [162]. These metabolites have a higher binding
aﬃnity for CB1 and CB2 receptors compared to 2-AG, whereas the
corresponding oxidized metabolites from AA (11,12-EET and 14,15-
EET) do not display any CB1 or CB2 receptor aﬃnity. Incubation of 2-
AG with the predominant CYP450 in the heart (CYP2J2 epoxygenase)
produces 2-11, 12- and 2-14, 15-EET-EG in vitro [163]. In addition,
heart microsomes derived from bovine and porcine tissues also pro-
duced 2-11, 12- and 2-14, 15-EET-EG. Yet, the physiological relevance
of these CYP450 metabolites remains to be elucidated.
4. 2-AG transport
In contrast to polar neurotransmitters that are stored in vesicles,
AEA and 2-AG are neutral lipids that have the intrinsic tendency to
associate with membranes. It is poorly understood how 2-AG and AEA
move across the synapse and traverse within the cellular interior, and
how cellular uptake of 2-AG and AEA is regulated. Possible routes for 2-
AG and AEA transmembrane transport are passive diﬀusion, en-
docytosis, transporter proteins, or a combination of these mechanisms.
The transport of AEA has been subject of intensive research, but the
mechanisms of uptake and transport of this endocannabinoid are still
under debate (for reviews see Niculussi & Gertsch [164], and Fowler
[165,166]). Fewer studies have addressed the transport process of 2-
AG, because its metabolism complicates the analysis of the transport
processes. Ben Shabat and colleagues found the ﬁrst indication of cel-
lular 2-AG uptake [167]. Co-incubation of 2-AG with 2-lineoyl-glycerol
reduced 2-AG depletion from media, while 2-palmitoyl-glycerol had no
eﬀect [167]. 2-AG accumulation in rat basophilic RBL-2H3 and mouse
neuroblastoma N18TG2 cells was also observed by Di Marzo et al.
[168]. Saturable 2-AG uptake by human astrocytoma cells, with a Mi-
chaelis-Menten constant (Km) of 0.7± 0.1 μM and a Vmax of 28±6
(pmol/min)/mg, indicated the existence of a speciﬁc transporter pro-
tein [169]. In addition, 2-AG uptake could be inhibited by AEA and the
putative AEA transport inhibitor AM404 (Table 1) [170,171]. Recently,
it was found that UCM707 and OMDM-2 (Table 1) could also inhibit 2-
AG and AEA uptake with equal potency. Thus, a common carrier me-
chanism was proposed for both AEA and 2-AG [172]. Importantly, not
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only the uptake could be blocked, but also the release of 2-AG, which is
suggestive of a bidirectional traﬃcking of 2-AG via its putative trans-
porter. Such an in and out transport through the plasma membrane has
been indeed documented for AEA [173,174]. Identiﬁcation, and func-
tional characterization of the putative transporter protein(s) will be
highly important for a better understanding of 2-AG storage, release
and transport. Noteworthy, evidence for intracellular 2-AG transport
was recently reported. A ﬂuorescence polarization assay with a NBD-
stearate probe showed that 2-AG (as well as AEA) bind to the cytosolic
carrier protein fatty acid binding protein (FABP) 5 [175]. Further evi-
dence for this binding was provided in a co-crystalization study of
FABP5 and 2-AG [176]. It would be interesting to see to what degree
FABP5 regulates the physiological role of 2-AG. Of note, also for the
other major endocannabinoid AEA diﬀerent intracellular transporters
(e.g., diﬀerent FABPs and heat shock protein 70) have been identiﬁed
that ferry it to the correct ﬁnal destination [143], as well as extra-
cellular transporters like microvesicles that ferry it through the synaptic
cleft [177].
5. Non-CB1/CB2 receptors targeted by 2-AG
Interestingly, several reports indicate that 2-AG may also produce
physiological eﬀects independently of CB1 and CB2 receptors, for in-
stance by binding to and activating GABAA [178], PPARγ [179], Ade-
nosine A3 [180], TRPV1 [181], and GPR55 [182]. For example, it has
been shown that 2-AG potentiates GABAA receptor function at low
GABA concentrations, which leads to inhibition of motility [178]. It
was also shown that 2-AG binds at the M4 transmembrane region of the
β2 subunit, and the observed eﬀect was still present in CB1/CB2 double
knockout mice [178]. These interactions with GABAA receptors can
have important implications on studies that interrogate 2-AG role on
sedation and locomotion [178]. In addition, 2-AG has been reported to
reduce interleukin (IL)2 expression via a PPAR-γ in splenocytes from
CB1/CB2 null mice [179,183]. However, it is not completely clear if this
interaction is mediated by 2-AG itself or through COX2-generated me-
tabolites thereof [183].
Adenosine is an orthosteric endogenous ligand for the adenosine A3
receptor. This GPCR plays an important role in modulation of in-
ﬂammation [184]. 2-AG acts as a negative allosteric modulator of
human adenosine A3 receptor binding. Therefore, adenosine A3 re-
ceptors can trigger potentially alternative pathways for 2-AG to mediate
inﬂammatory responses [185]. Moreover, 2-AG has also been reported
to act as a ligand for the TRPV1 receptor, which is an outwardly rec-
tifying Ca2+ permeable nonselective cation channel. The latter receptor
is activated by stimuli such as heat (T>42oC) and low extracellular
pH, and also by endogenous ligands including lysophosphatidic acid
and AEA. TRPV1 plays an important role in the regulation of core body
temperature and inﬂammatory pain [186]. Therefore, TRPV1 is an
important target to consider when studying the relation between 2-AG
and pain sensation [181,187–189]. Rydberg et al. showed that 2-AG has
a high aﬃnity for GPR55 in vitro [182]. The latter receptor has been
linked to energy balance and is a potential drug target for various
cancer types [190]. Of note, not only 2-AG but also other en-
docannabinoids show aﬃnity for GPR55, including virodhamine, AEA,
oleamide and noladin ether. Together, these studies indicate that 2-AG
has a wide variety of targets distinct from the classical cannabinoid
receptors (Table 2). To a large extent, the physiological relevance of
these non-CB1/CB2 receptors remains yet to be established in vivo, and
further research is deemed necessary to reveal the actual physiological
eﬀects governed by 2-AG through them.
6. Physiological eﬀects of 2-AG within the brain
During the last decade multiple lines of research have allowed to
gain insight in the physiological role of 2-AG. In the following section
we will discuss distinct pharmacological tools (Table 1) used to
manipulate 2-AG levels, as well as genetic manipulations of its target
receptors and metabolic enzymes that have uncovered the biological
role of 2-AG and its metabolites in brain function.
6.1. Food intake and metabolism
The intimate link between the endocannabinoid system and energy
balance is well-established [201]. CB1 receptor knockout mice display a
lean phenotype, reduced adiposity and feeding eﬃciency. When fed a
high fat diet, they display decreased triglyceride, plasma insulin, cho-
lesterol, and leptin levels, while having increased adiponectin levels
compared to their wild-type littermates [202,203]. This phenotype can
be mirrored by treatment of wild-type animals with the CB1 inverse
agonist rimonabant (Table 1) [204]. Importantly, rimonabant was ap-
proved on the European market in 2006 as a drug for the treatment of
obesity. However, it was soon withdrawn in 2008, due to serious psy-
chiatric side eﬀects, in particular depression.
Several lines of evidence indicate that 2-AG is, to a large extent,
responsible for CB1 mediated regulation of food intake and energy
metabolism. Fasting increased levels of 2-AG in limbic forebrain and
hypothalamus. Additionally, bilateral injection of 2-AG into the nucleus
accumbens stimulated increased feeding, and pretreatment with rimo-
nabant could reduce the eﬀect elicited by 2-AG infusion [205]. DAGL-α
knockout mice showed a similar phenotype to CB1 knockout mice with
decreased body weight and low triglycerides, cholesterol and insulin
levels [206]. Such a phenotype was not observed in DAGL-β knockout
mice, pointing to 2-AG biosynthesis by DAGL-α as the underlying me-
chanism. Acute disruption of DAGL activity by (i.p.) administration of
O-7460, a ﬂuorophosphonate-based DAGL inhibitor, dose dependently
inhibited intake of high fat diet in mice [56]. This is in line with a
previous report where the DAGL inhibitor O-5596 reduced the intake of
palatable food in these animals [57].
Jung et al. provided further evidence for the involvement of 2-AG in
metabolism [207]. Upregulation of 2-AG hydrolysis by overexpression
of MAGL in the mouse forebrain led to a 50% decrease of 2-AG levels in
this brain region, but did not aﬀect AEA or AA levels. These mice were
lean, hyperphagic, resistant to diet-induced obesity, hyperthermic and
hypersensitive to β3-adrengenic-stimulated thermogenesis. MAGL in-
hibition with JZL184 showed that restoring 2-AG signaling at CB1 re-
ceptors normalized β3-adrengenic-dependent thermogenesis, sug-
gesting that such a signaling pathway helps to conserve body energy by
sparing heat production.
Despite rimonabant retraction from the market, enzymes re-
sponsible for the biosynthesis of 2-AG remain interesting drug targets
for the treatment of the metabolic syndrome. Their partial inhibition,
subtype selectivity and/or the ability to keep other CB1 signaling
pathways (e.g. AEA) intact, may prevent psychiatric side-eﬀects.
6.2. Neuro-inﬂammation
2-AG plays a central role in the regulation of multiple neuro-in-
ﬂammatory processes in the brain. Previously, phospholipase A2 (PLA2)
was considered the primary source of AA for COX-mediated biosynth-
esis of prostaglandins, but this view has signiﬁcantly changed in recent
years. Nomura et al. showed that hydrolysis of 2-AG by MAGL provides
the major pool of AA for the generation of neuro-inﬂammatory eico-
sanoids in speciﬁc tissues, such as brain, liver and lungs [116]. Con-
sistently, chemical inhibition or genetic disruption of MAGL activity
lowered lipopolysaccharide (LPS)-induced pro-inﬂammatory eicosa-
noid production in the brain, such as PGE2, PGD2, PGF2, and throm-
boxane B2 (TXB2), via a CB1 and CB2 receptor-independent mechanism.
In addition, abolishment of MAGL activity did not aﬀect basal cytokine
levels, but almost completely blocked LPS-induced elevation of inter-
leukin-1α (IL-1α), IL-1β, IL-6 and TNF-α. Speciﬁc knockdown of MAGL
in astrocytes moderately elevated 2-AG levels and did not cause CB1
receptor desensitization nor any behavioral eﬀect; yet, it decreased
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cytokine and prostaglandin levels via a CB1/CB2 independent me-
chanism [208]. This is in line with the anti-inﬂammatory eﬀects ob-
served when blocking 2-AG biosynthesis. DAGL-α/β inhibitors DO34
and DH376 reduced brain levels of 2-AG, AA and AEA [39]. Pro-in-
ﬂammatory prostaglandins PGE2 and PGD2 and cytokine IL-1β were
also reduced in LPS-treated animals. In keeping with these observa-
tions, Viader et al. showed that DAGL-β is important for regulation of 2-
AG levels in microglia without aﬀecting global 2-AG and prostaglandin
levels in the brain [78]. Finally, LPS-induced anapyrexia, that lowers
core body temperature, was substantially reduced in DAGL-α and
DAGL-β KO as well as in inhibitor-treated mice [78], an observation
that extends an independent report showing increased anapyrexia in
MAGL inhibitor-treated mice [209]. These data imply an important role
for 2-AG in the regulation of body temperature.
In addition to playing a pro-inﬂammatory role by promoting PGs
biosynthesis, 2-AG is also neuroprotective. For example, in 2001
Panikashvili et al. reported neuroprotection by 2-AG in a traumatic
brain injury model [210]. After inﬂiction of closed head injury, a strong
elevation (up to 10-fold increase after 4h) of mouse brain 2-AG levels
was observed. Injection of exogenous 2-AG elicited a neuroprotective
eﬀect, which was absent in CB1 knockout models and after pretreat-
ment with the CB1 receptor antagonist rimonabant. Neuro-inﬂamma-
tion is one of the early neurochemical responses after closed head injury
[211], and consistently 2-AG has been shown to inhibit NFκ-B trans-
activation and to reduce acute expression of the pro-inﬂammatory cy-
tokines TNF-α, IL-1β and IL-6 via CB1-dependent signaling [212].
Of note, common neurological disorders like Multiple Sclerosis
(MS), Parkinson's disease (PD) and Alzheimer's disease (AD) have a
Table 2
2-AG-interacting proteins.
Receptor Ligand Ki, IC50 or EC50 Additional ligands physiological eﬀect Referencea
Receptor
interaction
CB1 2-AG Ki= 34.6–472 nMb AEA, Virodhamine, Noladin ether [191], NADA [192],
oleamide [193], DTEAc [194], HLEAd [194], EPEAe [195],
DHEAf [195], Hemopressin[196]
Anxiety, pain, metabolism,
addiction, inﬂammation
[3], [167]
CB2 2-AG Ki= 1400 nMb AEA, Noladin ether [191], NADA [192], DLEA [194],
EPEA [195], DHEA [195]
Inﬂammation [3]
TRPV1 2-AG EC50= 2.5 μMg AEA, NADA [197] Pain [181]
GABAA 2-AG EC50 = 2.1 μMh GABA [178]
A3 2-AG IC50 = 12.6 μMi Adenosine [180]
GPR55 2-AG EC50 = 3 nMj Lyso-PI, AEA, noladin ether, virodhamine [182]
PPARγ 2-AG EC50 = 10 μMk Prostaglandins Inﬂammation [179]
Enzyme substrate Km Additional substrates physiological eﬀect Reference
Biosynthesis DAGL-α DG (18:0/
20:4)
155 μMl DG(18:1/18:1), DG(18:1/18:0), DG (16:0/18:0),
DG(16:0/20:4), DG(18:1/20:4).
metabolism, anxiety,
inﬂammation
[40]
DAGL-β DG (18:0/
20:4)
74 μMl DG(18:1/18:1), DG(18:1/18:0) Inﬂammation [40]
DDHD2 DG (18:0/
20:4)
248 μMm TAG species with diﬀerent combinations of C16:0, C18:0,
C18:1, C20:4, C22:5, C22:6 fatty acyl chains [50]
(DG 18:0/18:2), DG (18/22:6).
– [49,198]
2-LPA
Phosphatase
2-AG-LPA - Oleoyl-LPA – [52]
Lyso PI-PLC 2-AG-LPI - LysoPC, LysoPS [199] – [4,51]
Enzyme Metabolite Km Additional substrates physiological eﬀect Reference
Metabolism MAGL AA 110 μMn MG (18:1), MG(18:2) [102] MAG (16:0), MAG (18:1), MG
(18:2), MG (22:6) [101]
Anxiety, pain, addiction,
metabolism
[118]
ABHD6 AA 159 μMn MG(14:0), MG(16:0), MG(18:0), MG(18:1) [200] in vivo in
BAT ABHD6 KO mice.
Inﬂammation, metabolism [118]
ABHD12 AA 117 μMn LPS(16:0), (18:0), (20:4), (22:4), (22:1), (22:0), (18:0),
(18:0) and PS(16:0/18:1), (18:1/18:1), (16:1/20:4),
(18:1/20:4), (18:0/20:4), (20:1/20:4), (20:0/20:4), (22:1/
20:4), (22:0/20:4), (24:1/20:4) [134]
Inﬂammation [118]
COX2 PGE2-G 4.4 μMo AA, AEA [66] Inﬂammation [145]
LOX12 12-HpETE-G 6 μMp AA, AEA, linoleic acid, docohexanoic acid Inﬂammation [157]
LOX15-2 15-HpETE-G 9 μMq AA, AEA Inﬂammation [158]
CYP2J2 11,12-EET-G 13.6 μMr AA, AEA Inﬂammation [160,163]
14,15-EET-G 32.6 μMr
a Reference regarding the Ki, Km, IC50 or EC50.
b Range of Ki‘s measured by ligand displacement assay with [3H]HU-243 in membranes fractions of COS cells transfected with the corresponding receptor [3,167].
c DTEA: docosatetraenoylethanolamide.
d HLEA: homo-γ-linolenoylethanolamide.
e EPEA: eicosapentaenoylethanolamide.
f DHEA: docosahexaenoylethanolamide.
g Eﬀect on intracellular calcium concentration in TRPV1 expressing HK293 cells, maximum responses were normalized to the 10 μM capsaicin-induced response.
h Dose-dependent potentiation of currents elicited by 1 μM GABA.
i Ligand displacement assay with [125I] AB MECA in CHO membranes expressing the hA3 receptor.
j GTPγS binding assay.
k IC50 competition for ﬂuorescent ligand occupancy the puriﬁed PPARγ ligand binding domain.
l Membrane of COS cell overexpressing DAGL-α or DAGL-β respectively.
m Recombinant rDDHD2.
n
ﬂuorescent glycerol assay for 2-AG hydrolase activity in HEK293 cells transiently transfected with the corresponding hydrolase.
o Oxygenation by puriﬁed human COX2 [145].
p UV assay for the conjugated diene (leukocyte LOX12) [157]. qHexahistidine-tagged human 15 LOX-2 expressed in Sf-9 cells and puriﬁed on Ni-NTA agarose.
r Formation kinetics for CYP2J2 nanodisc incubations with 2-arachidonoyl glycerol.
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major neuro-inﬂammatory component [213–215]. Consequently,
modulation of MAGL activity has been tested in various animal models
of neurodegenerative diseases (Table 3). Nomura et al. used a 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD [116],
where JZL184 provided neuroprotective eﬀects that were not reversed
by the CB receptor antagonists, but were recapitulated by COX inhibi-
tion. These ﬁndings indicate that the neuroprotective eﬀects were not
mediated via CB receptors, but were rather due to reductions in AA and
proinﬂammatory prostaglandins. Later on, Mounsey et al. conﬁrmed
this hypothesis [216].
Perturbation of MAGL activity has also been investigated in animal
models of AD, such as 5XFAD and PS1/APP+ mice. Genetic and phar-
macological inactivation of MAGL suppresses proinﬂammatory re-
sponses and amyloidosis in a PS1/APP+ AD mice [217]. Moreover, in
5XFAD AD mice, inhibition of MAGL reduces production and accumu-
lation of β-amyloid (Aβ) and improves cognitive function [218]. In
mice suﬀering from experimental autoimmune encephalitis (EAE), a
mouse model for of MS, inhibition of MAGL activity reduced the se-
verity of the clinical symptoms [61,62]. Additionally, inhibition of
DAGL with the ﬂuorophosphonate-based inhibitor O-3841 was neuro-
protective in a malonate model of Huntington's disease (HD) in rat
brain [219]. In contrast, inhibition of MAGL activity and administration
of PGE2-G worsened malonate-induced injury. Therefore, oxidative
metabolites of 2-AG have been suggested to play a role in cytotoxicity
ultimately leading to HD.
6.3. Anxiety
Endocannabinoid signaling via CB1 receptor has a primary role in
modulating anxiety and depressive behaviors [36,220]. The eﬀects of
CB1 receptor agonists on anxiety are complex and show biphasic eﬀects,
with low agonist doses leading to anxiolytic eﬀects [221,222], and high
doses leading to anxiogenic eﬀects [223]. Pharmacological blockade
and genetic deletion of the CB1 receptor has been shown to increase
anxiety [221,224–227]. Both AEA and 2-AG play an important role in
stress and anxiety. Studies have generally shown a bidirectional eﬀect
of stress on endocannabinoid levels, AEA levels decreasing and 2-AG
levels increasing compared to controls [228,229]. Interestingly, several
studies support the hypothesis that glucocorticoids modulate GABA and
glutamate release via enhanced endocannabinoid signaling at the CB1
receptor [230]. Glucocorticoid hormones that are released as a result of
stress recruit 2-AG and promote termination of hypothalamic-pituitary-
adrenocortical (HPA) axis activity [231,232]. In line with this, it has
been shown that levels of 2-AG are signiﬁcantly elevated by corticos-
terone treatment and strain-induced stress [233,234]. Elevation of AEA
levels by genetic deletion or pharmacological inhibition of FAAH has
shown anxiolytic eﬀects in several independent studies [221,235–237].
More recently, the role of 2-AG in anxiety-like behavior has been stu-
died. Shonesy et al. investigated the role of DAGL-α in anxiety [238],
documenting increased anxiety and depressive behavior in DAGL-α KO
mice. This eﬀect was reversed by normalization of 2-AG content
through pharmacological inhibition of MAGL. Furthermore, anxiolytic
eﬀects are observed when 2-AG levels are increased by treatment with
JZL184 [59,112,114,239–241]. These data show that 2-AG, rather than
its downstream metabolites, reduces anxiety. In line with this hypoth-
esis, Jenniches et al. also observed a similar anxiogenic phenotype in
DAGL-α knockout mice [242]. Bluett et al. investigated the role of 2-AG
in stress resilience in mice [85], showing that acute systemic 2-AG
augmentation promotes it. In contrast, CB1 receptor blockade or phar-
macological inhibition of DAGL by DO34 allowed stress-resilient mice
to develop anxiety-like behavior after acute stress exposure. The latter
ﬁnding demonstrates that acute blockade of DAGL-α also results in
anxiogenic behavior. Remarkably, in most of the above studies the
anxiolytic eﬀect could be blocked by rimonabant, indicating a likely
engagement of CB1 [59,85].
6.4. Addiction
The endocannabinoid system has been implicated in multiple as-
pects of addiction [37,243,244]. CB1 receptor agonists have been
shown to alleviate withdrawal symptoms [245,246], while inverse
agonists and antagonists reduce nicotine self-administration [244].
Several lines of evidence indicate an important role for 2-AG in ad-
dictive behavior and withdrawal. Injection of exogenous 2-AG was
moderately eﬀective in reducing the intensity of precipitated with-
drawal signs in morphine-dependent mice [246], whereas Ramesh et al.
[247] showed that JZL184 could completely prevent naloxone-pre-
cipitated morphine withdrawal symptoms, including paw ﬂutters,
Table 3
Eﬀect of 2-AG modulation in neuro-inﬂammation.
Disease Target Compound and/or
knockout (KO)
2-AG
levels
Eﬀect Species Model CB receptor
mediated
Ref.
Neuro-inﬂammation MAGL JZL184, KO ↑ Reduction of eicosanoid production Mouse LPS treatment No [116]
DAGL DO34, DH376, KO ↓ No [39]
MAGL JZL184 ↑ Exacerbates LPS induced anapyrexia Yes [209]
DAGL DO34, DH376, KO ↓ Attenuates LPS induced anapyrexia – [39]
DAGL-β KO ↓ – [78]
MAGL Speciﬁc KO in
astrocytes
↑ Reduction of PGE2 andcytokine levels No [208]
Parkinson's Disease
(PD)
MAGL JZL184, KO ↑ Neuroprotection (prevented MPTP-
induced dopaminergic neuronal loss)
(MPTP) mouse
Model of Parkinsonism
No [116]
MAGL JZL184 ↑ No [216]
Alzheimer's disease
(AD)
MAGL JZL184, KO ↑ Attenuate prostaglandin and β-amyloid
(Aβ) levels
PS1/APP+
AD Mouse Model
No [217]
MAGL JZL184, KO ↑ Reduction of neurodegeneration 5XFAD APP transgenic mice,
a mouse
Model of AD
No [218]
Multiple sclerosis (MS) MAGL Compound 21a ↑ Decreasing tissue damage Autoimmune ence-phalitis
(EAE) mouse model MS
– [62]
MAGL Compound 4ab ↑ Amelioration of the course of
demyelination
Partially [61]
Huntington's disease
(HD)
DAGL O-3841 ↓ Attenuation malonate-induced GABA
and BDNF deﬁciencies
Rat Malonate model of HD – [219]
MAGL JZL184 ↑ Exacerbation malonate-induced striatal
damage
– [219]
a INH21: Benzo [d][1,3]dioxol-5-ylmethyl 6-([1,1'-biphenyl]-4-yl)hexanoate, named compound 4a in Brindisi et al. [61].
b INH4a: trans-(1-(1-(1H-1,2,4-Triazole-1-carbonyl)piperidin-4-yl)-4-benzo[d][1,3]dioxol-5-yl)-3-(4-ﬂuorophenyl)azetidin-2-one, named compound 21 in
Hernandez-Torres et al. [62].
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diarrhea, jumps, and weight loss. These eﬀects were blocked by rimo-
nabant, suggesting a CB1 receptor-mediated eﬀect. Importantly, so-
matic and aversive withdrawal signs in nicotine-dependent mice were
reduced by both genetic and pharmacological inactivation of MAGL via
a CB1 receptor-mediated mechanism [248].
A study by McReynolds et al. suggests that stress-induced relapse to
cocaine seeking depends on 2-AG and is reduced by CB1 receptor an-
tagonism [243,249,250]. In keeping with experiments with CB1 re-
ceptor antagonists [251], reduction of 2-AG levels by inhibition of its
biosynthetic enzymes DAGL-α and DAGL-β reduced nicotine self-ad-
ministration in mice. Release of the inhibitory neurotransmitter GABA
was diminished upon chronic nicotine exposure [244,252]. To gain
insight into the underlying mechanism, the eﬀect of DAGL inhibition on
GABA signaling was studied. The DAGL blocker 1,2,3-triazole urea
KT172 rescued GABAergic signaling at dopaminergic neurons in the
vental tagmental area [252]. Conversely, increasing 2-AG signaling by
blocking MAGL recapitulated the loss of nicotine-induced GABA sig-
naling following chronic nicotine exposure.
6.5. Pain
Cannabinoids have been used for their ability to reduce pain for
many centuries [253]. The anti-nociceptive eﬀects appear to be medi-
ated by CB1 receptors within the CNS [254,255], and via both CB1 and
CB2 receptors at the periphery [33,256,257]. Stimulation of both CB
receptor subtypes by AEA or 2-AG shows analgesic eﬀects. The role of
AEA in pain sensation has been well-documented. Elevation of AEA
levels by inhibition or genetic ablation of FAAH, and administration of
AEA elicit anti-nociceptive eﬀects (see Guindon and Hohmann [258],
and Schlosburg et al. [259] for extensive reviews).
Elevation of 2-AG has been observed in preclinical models of in-
ﬂammatory pain [260,261]. Various studies have demonstrated an
analgesic eﬀect of local administration of 2-AG [262,263], as well as by
increasing endogenous 2-AG levels via MAGL inhibitors in various pain
models [264–266], including neuropathic pain [267], peripheral in-
ﬂammatory pain [115], gastrointestinal pain [268] and chemotherapy-
induced neuropathy (Table 4) [269,270]. Anti-nociceptive eﬀects of 2-
AG are likely mediated by CB1 receptors. Long et al. and Kinsey et al.
showed that the eﬀect of MAGL inhibition on thermal, noxious che-
mical, and neuropathic pain sensation were blocked by the CB1 receptor
inverse agonist rimonabant [59,269]. Important to note is that the anti-
nociceptive eﬀect was absent or largely reduced in MAGL knockout
mice and upon chronic treatment with MAGL inhibitors, an observation
that can be explained by CB1 receptor desensitization and/or
downregulation [100,101]. Intracerebroventricular injection of JZL184
produced TRPV1-dependent anti-nociception in the mouse formalin
test, which indicates that anti-nociceptive eﬀects are also mediated by
vanilloid receptors [189]. Recently, inhibition of DAGL-β was reported
to reduce nociception in preclinical models of inﬂammatory and neu-
ropathic pain, which might be explained by a reduction of pro-in-
ﬂammatory prostaglandins [271]. Taken together, these data demon-
strate an important role for 2-AG in pain sensation via multiple
mechanisms, including TRPV1, CB1, and CB2 signaling, and as a pre-
cursor for prostaglandins that modulate inﬂammation and pain.
7. Conclusions
CB1 receptor is the major brain target through which 2-AG exerts its
physiological eﬀects, including regulation of food intake and metabo-
lism, neuro-inﬂammation, addiction, anxiety and pain. In addition to
classical CB receptors, 2-AG has shown remarkable aﬃnity for other
receptor targets, including GABAA, adenosine A3, TRPV1, PPARγ and
GPR55 receptor. To date it is, however, unknown whether these pro-
teins are involved in physiological eﬀects of 2-AG in vivo. Next to its
function as a signaling lipid, 2-AG is also a key intermediate of multiple
lipid metabolic pathways. A number of 2-AG metabolites have im-
portant signaling functions in their own right. 2-AG is a key precursor
for the biosynthesis of eicosanoids in the brain, which in turn propagate
inﬂammation [146]. Its involvement in major (patho)physiological
processes makes modulation of 2-AG levels an interesting strategy from
a therapeutic perspective.
Modulation of 2-AG levels in vivo, in particular by blocking MAGL or
DAGL activity, triggers multidirectional eﬀects in various (patho)phy-
siological processes (Fig. 2). Reduction of 2-AG levels by blocking its
major DAGL-α/β biosynthetic pathway can be beneﬁcial for treatment
of the metabolic syndrome, addiction, and neuro-inﬂammatory dis-
orders, while elevation of 2-AG levels by blocking MAGL, the major
pathway releasing AA, reduces neuro-inﬂammation, anxiety-related
behavior, withdrawal symptoms and nociception. However, its prime
role in multiple important physiological pathways puts modulation of
2-AG levels at risk of unwanted eﬀects (Fig. 2). The essential role of
endocannabinoid signaling in the brain was emphasized by the with-
drawal of the CB1 inverse agonist and anti-obesity drug rimonabant
from the European market, because of severe neuropsychiatric side
eﬀects.
It is important to note that not all behavioral phenotypes of CB1 KO
mice were mirrored by DAGL-α KO mice, which showed less anxiogenic
behavior compared to CB1 KO mice in open ﬁeld test and platform tests
Table 4
2-AG modulation in pain.
Modulation Enzyme Inhibitor 2-AG Eﬀect Species Model Receptor Ref.
Genetic MAGL – ↑ No eﬀect compared to
wild-type
Mouse Tail-immersion test for thermal nociception CB1 [101]
– ↑ No eﬀect compared to
wild-type
Mouse Inﬂammatory complete Freund's adjuvant and neuropathic spinal
Nerve ligation pain
CB1 [100]
Inhibition MAGL JZL184 ↑ Anti-nociceptive Mouse Intraplantar formalin injection TRPV1 [189]
URB602 ↑ Anti-nociceptive Rat Radiant-heat tail-ﬂick test CB1 [266]
JZL184 ↑ Anti-nociceptive Mouse Tail-immersion test for thermal nociception CB1 [272]
JZL184 ↑ Anti-nociceptive Mouse Tail-immersion test for thermal nociception CB1 [101]
JZL184 ↑ Anti-nociceptive Rat Mechanical and cold allodynia (cisplatin induced) CB1, CB2 [267]
JZL184 ↑ Reduction of mechanical
allodynia
Mouse Mechanical allodynia (carrageenan) CB1, CB2 [115]
JZL184 ↑ Reduction of allodynia Mouse Chronic constriction injury induced allodynia CB1 [270]
OMDM169 ↑ Anti-nociceptive Mouse Formalin test CB1, CB2 [64]
JZL184 ↑ Reduction of allodynia Mouse Chronic constriction injury induced allodynia CB1 [269]
SAR127303 ↑ Anti-nociceptive Mouse Phenylbenzoquinone-induced writhing model of acute visceral pain and
formalin test of inﬂammatory pain
CB1 [29]
URB602 ↑ Anti-nociceptive Mouse Plethysmometer and plantar test CB2 [273]
DAGL KT109 ↓ Reversal of LPS-induced
allodynia
Mouse Chronic constriction injury, and paclitaxel model of chemotherapy-
induced neuropathic pain
NT [271]
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[206]. These diﬀerences can be partly explained by keeping other CB1
signaling pathways intact, (e.g., those mediated by AEA) when mod-
ulating 2-AG levels. Therefore, selective modulation of 2-AG metabo-
lism can help to dissect the signaling tasks of 2-AG and AEA, and po-
tentially circumvent adverse eﬀects observed by direct blockade of CB1
receptors. In addition, elevation of 2-AG levels by blockade of MAGL
does not cause the full spectrum of behavioral eﬀects observed with
direct (endo)cannabinoid agonists, such as hypothermia and catalepsy
[94,272]. Moreover, a study by Fagundo et al. suggests that elevated
levels of AEA are associated with an improvement of decision making
and cognitive ﬂexibility, while elevated 2-AG levels were associated
with an opposite eﬀect [274]. These studies demonstrate overt func-
tional diﬀerences between AEA and 2-AG [275].
Although modulation of 2-AG levels does not reproduce all unto-
ward eﬀects observed with direct CB1 modulation, several adverse ef-
fects have been observed upon pharmacological or genetic disruption of
the major metabolic pathways of 2-AG. Chronic blockade of MAGL
causes desensitization and down-regulation of CB1 receptor, while
disruption of DAGL increases anxiety, maternal neglect and reduces fear
extinction. Therefore, ﬁnely-tuned rather than complete disruption of
2-AG metabolism could be a promising approach to establish a ther-
apeutic window. The latter can be achieved via diﬀerent strategies: 1)
partial blockade of major biosynthetic (DAGL) or hydrolytic (MAGL)
pathways; or 2) targeting 2-AG metabolizing enzymes that give a
smaller contribution to bulk 2-AG regulation compared to DAGL and
MAGL.
Lowering 2-AG levels by partial blockade of the DAGL pathway can
be achieved by subtype-selective DAGL inhibitors. DAGL-β has been
shown to reduce inﬂammatory responses in vivo without aﬀecting sy-
naptic transmission [78]. Moreover, incomplete inhibition of DAGL
enzymes can be used to tweak endocannabinoid tone. Conversely,
moderate increase of 2-AG could be achieved by partial inhibition of
MAGL. To this aim, both MAGL and DAGL reversible inhibitors would
be highly valuable tools. The in vivo role of enzymes that contribute in a
less deﬁned manner to metabolism (ABHD 2, 6 and 12, COX-2, LOX and
CytP450), transport (FABP5) and signaling of 2-AG (GABAA, adenosine
A3, TRPV1, PPARγ, and GPR55), requires further investigation. Future
research on these proteins might uncover new physiological roles of 2-
AG and novel approaches to modulate its (patho)physiological eﬀects.
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